

Title (en)  
METHOD FOR PRODUCING (3S)-3-(4-CHLOR-3-[[[(2S,3R)-2-(4-CHLORPHENYL)-4,4,4-TRIFLUOR-3-METHYLBUTANOYL]AMINO}PHENYL]-3-CYCLO-PROPYLPROPANOIC ACID AND THE CRYSTALLINE FORM THEREOF FOR USE AS A PHARMACEUTICAL INGREDIENT

Title (de)  
VERFAHREN ZUR HERSTELLUNG VON (3S)-3-(4-CHLOR-3-[[[(2S,3R)-2-(4-CHLORPHENYL)-4,4,4-TRIFLUOR-3-METHYLBUTANOYL]AMINO}PHENYL]-3-CYCLOPROPYLPROPANSÄURE UND DESSEN KRISTALLINE FORM FÜR DIE VERWENDUNG ALS PHARMAZEUTISCHER WIRKSTOFF

Title (fr)  
PROCÉDÉ DE PRÉPARATION D'ACIDE (3S)-3-(4-CHLORO-3-[[[(2S,3R)-2-(4-CHLOROPHÉNYL)-4,4,4-TRIFLUORO-3-MÉTHYLBUTANOYL]AMINO}PHÉNYL]-3-CYCLOPROPYLPROPANOÏQUE ET SA FORME CRISTALLINE POUR UNE UTILISATION EN TANT QUE PRINCIPE ACTIF PHARMACEUTIQUE

Publication  
**EP 3717480 A1 20201007 (DE)**

Application  
**EP 18814516 A 20181126**

Priority  
• EP 17204842 A 20171201  
• EP 2018082526 W 20181126

Abstract (en)  
[origin: WO2019105881A1] The invention relates to a novel and improved method for producing (3S)-3-(4-chlor-3-[[[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluor-3-methylbutanoyl]amino}phenyl]-3-cyclo-propylpropanoic acid of the formula (I), to the compound of the formula (I) in a crystalline form, and to the use thereof for treating and/or preventing diseases, in particular for treating and/or preventing cardiovascular, cardiopulmonary, and cardiorenal diseases.

IPC 8 full level  
**C07D 453/04** (2006.01); **C07C 57/30** (2006.01); **C07C 57/32** (2006.01); **C07C 57/42** (2006.01); **C07C 215/42** (2006.01); **C07C 233/55** (2006.01)

CPC (source: EP IL KR US)  
**A61K 31/167** (2013.01 - KR); **A61P 9/00** (2017.12 - KR); **C07C 51/09** (2013.01 - EP IL KR US); **C07C 51/487** (2013.01 - EP IL KR); **C07C 53/18** (2013.01 - KR); **C07C 57/58** (2013.01 - IL); **C07C 67/08** (2013.01 - EP IL KR); **C07C 67/303** (2013.01 - EP IL KR); **C07C 67/327** (2013.01 - EP IL KR); **C07C 67/333** (2013.01 - EP IL KR); **C07C 67/343** (2013.01 - EP IL KR); **C07C 67/54** (2013.01 - EP IL KR); **C07C 69/608** (2013.01 - IL); **C07C 69/63** (2013.01 - KR); **C07C 69/635** (2013.01 - IL); **C07C 69/65** (2013.01 - IL); **C07C 69/732** (2013.01 - IL); **C07C 227/18** (2013.01 - US); **C07C 231/02** (2013.01 - EP IL KR US); **C07C 231/12** (2013.01 - US); **C07C 233/54** (2013.01 - KR); **C07C 233/55** (2013.01 - IL); **C07C 233/88** (2013.01 - US); **C07D 453/04** (2013.01 - EP IL KR); **C07B 2200/07** (2013.01 - EP IL); **C07B 2200/13** (2013.01 - EP IL US); **C07C 2601/02** (2017.04 - EP IL KR); **Y02P 20/55** (2015.11 - EP)

Citation (search report)  
See references of WO 2019105881A1

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)  
BA ME

DOCDB simple family (publication)  
**WO 2019105881 A1 20190606**; AR 113852 A1 20200617; AU 2018374452 A1 20200604; BR 112020010837 A2 20201110; CA 3083986 A1 20190606; CL 2020001420 A1 20201023; CN 111433204 A 20200717; CO 2020006789 A2 20200831; EP 3717480 A1 20201007; IL 274715 A 20200730; JO P20200133 A1 20200531; JP 2021504396 A 20210215; KR 20200094762 A 20200807; MX 2020005646 A 20200820; MX 2022012998 A 20221108; PE 20211391 A1 20210727; RU 2020121714 A 20220104; SG 11202004577V A 20200629; TW 201936568 A 20190916; US 11332435 B2 20220517; US 2021179541 A1 20210617; US 2022234996 A1 20220728; UY 37987 A 20190628

DOCDB simple family (application)  
**EP 2018082526 W 20181126**; AR P180103492 A 20181128; AU 2018374452 A 20181126; BR 112020010837 A 20181126; CA 3083986 A 20181126; CL 2020001420 A 20200528; CN 201880077741 A 20181126; CO 2020006789 A 20200529; EP 18814516 A 20181126; IL 27471520 A 20200517; JO P20200133 A 20190601; JP 2020529297 A 20181126; KR 20207018515 A 20181126; MX 2020005646 A 20181126; MX 2022012998 A 20200713; PE 2020000635 A 20181126; RU 2020121714 A 20181126; SG 11202004577V A 20181126; TW 107142604 A 20181129; US 201816767724 A 20181126; US 202217722849 A 20220418; UY 37987 A 20181130